anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A brain tumor treatment composition which includes coltsfoot extracts and a health supplement are provided to prevent growth of brain tumor cells and induce apoptosis. CONSTITUTION: A brain tumor treatment composition which includes coltsfoot extracts includes the Farfarae Flos ethanol extract as an active ingredient. The ethanol extract is extracted at 50 deg. Celsius for 24 hours. The ethanol extract is dried and concentrated at 45 deg. Celsius under a decompression condition. The ethanol is 95% ethanol. The composition comprises a carrier or a diluent which is allowable in the pharmaceutical field. The composition is used for prevention and treatment for primary brain tumor of neuroma, astrocytoma, nervous tissue, glioma, exothelioma, oligodendroglioma, medulloblastoma, spinal cord tumor or neurilemmoma. The health supplement for prevention and treatment of brain tumor includes the Farfarae Flos ethanol extract which includes the allowable food additive. The functional food includes 0.1-5 weight% based on the total weight of ethanol extracts.
Patients in the Warfarin group take Warfarin 2-10mg once daily, dose adjusted with the target INR 2-3. In the elderly or frail patients, a lower dose administration is allowed at the discretion of the investigator.
INTRODUCTION: Post-stroke fatigue is an often overlooked problem that hinders recovery. Therefore, stroke patients should be evaluated for fatigue during the recovery period. This study aimed to adapt the Neurological Fatigue Index for Stroke (NFI-Stroke) into the Turkish language.
METHODS: This methodological study was carried out on 110 stroke patients admitted to a university hospital in Istanbul. In addition to the NFI-Stroke, Functional Independence Measure, National Institutes of Health Stroke Scale, modified-Rankin Scale, Fatigue Severity-Scale, and Stroke Self Efficacy Questionnaire were used to collect data.
RESULTS: Since the linguistic validity study of the scale has already been carried out, only psychometric properties were evaluated. The items in the scale were grouped under two factors. The Cronbach`s alpha coefficient was found to be 0.96 for the physical sub-dimension and 0.84 for the cognitive sub-dimension. Item-total correlation coefficients were found between 0.74-0.91 for the physical sub-dimension, and 0.82-0.91 for the cognitive sub-dimension. The test-retest evaluation confirmed the consistency of the responses to the scale against time. The scale was correlated with other scales used in the study as expected.
CONCLUSIONS: The NFI-Stroke will be useful in clinical practice in assessment of fatigue, which may affect the adaptation of patients to rehabilitation.
PROBLEM TO BE SOLVED: To obtain a constipation improver having a sufficient constipation improving effect with a small amount ingestion because of making a gelatinized film of water-soluble dietary fibers in dejection by a water holding property of sugar alcohol and accelerating transferring of content in an alimentary canal by using water-soluble dietary fibers and sugar alcohol together as active components. SOLUTION: This constipation improver contains (A) water-soluble dietary fibers (preferably carrageenan) and (B) sugar alcohol (preferably erythritol) as active components. Preferably, respectively 1-20 wt.% of the component A and B are contained in the constipation improver. Preferably, a containing weight ratio of the component A to B is (1/1)-(1/200). A total daily ingesting amount of the components A and B may be 1-30 g. Preferably, the objective constipation inhibitor is ingested as a peroral agent, e.g. made as an arbitrary shape such as a tablet, a drink or a food. Other than the components A and B, vitamins, insoluble dietary fibers, oligosaccharide, lactic acid bacteria, etc., can be mixed, as necessary.
In addition to the basic program described above, those randomized to this intervention will attend Parenting Training sessions with the mental health provider at FHC. Families assigned to parenting training will receive 10-12 sessions. Sessions will focus on topics like strategies to support the child's physical, social, and emotional growth. The wellness coach will try to minimize in-person meetings with FHC professionals each week and space out visits to reduce burden on families.
The invention belongs to the technical field of medicaments, and provides a method for preparing amentoflavone of which the content is over 95 percent from a Chinese medicament of herba selaginellae. The compound has a structure as shown in the formula (I). A dried herbal material of selaginella tamariscina(Beauv.)spring or selaginella pulvinata(Hook.et Grev.)maxim. is taken as an initial raw material, extracted by organic solvent and/or water, and separated by a column chromatography separation method to obtain the amentoflavone. The method has the advantages of simple process operation, goodrepeatability, high yield and the suitability for industrialized production; and the product is high in purity, and the content of the product is measured to be over 95 percent by an HPLC method.
This group consist of postmenopausal women diagnosed with bacterial vaginosis. All subjects will receive metronidazole oral 400-500 mg twice daily or 0,75% metronidazole gel 5 grams intravaginally once daily for 5 days, then blind-randomly including to the placebo group and will receive Cal95® probiotic tablets (Lapi, Indonesia) orally once daily for two weeks.
This group will receive a single dose of the PL+ omega 3 fatty acids capsules first, then receive a single dose of the standard FO EE omega 3 fatty acids capsules. Wash-out period is 2 weeks between treatments.
The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
A system for determining a region of interest in an image. The system includes a memory and an electronic processor. The electronic processor is configured to create an image pyramid for the image. The image pyramid includes a plurality of layers. For each layer of the image pyramid, the electronic processor is configured to initialize internal states of nodes of a spatial lattice and iteratively update the internal states of the nodes using spatially gated propagation. Each node in the spatial lattice represents a block of pixels in the image and is connected to a node representing a neighboring block of pixels in the image. The electronic processor is also configured to identify the region of interest based on the internal states of the nodes at a convergence of the spatial lattice having nodes representing values included in a first layer of the image pyramid.
Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
1-Carboxyalkanoyl perhydro-indole 2-carboxylic acids of formula (I), in which R4 is H or lower alkyl; R5 is lower alkyl substd. with phenyl opt. substd. with lower alkyl, alkoxy or other gps. and t is 0 or 1, and their acceptable salts are made by condensing an acid of formula (II) with an acid of formula (III) or its functional deriv. in presence of condensing agents, e.g. organic or inorganic bases.
PURPOSE: A novel microorganism Acinetobacter baumannii KCTC18184P with excellent biofilm-forming ability is provided to develop a therapeutic agent for treating infectious diseases. CONSTITUTION: A novel microorganism Acinetobacter baumannii KCTC19194P forms a biofilm. Acinetobacter baumannii contains a gene encoding a protein with function of suppressing biofilm formation. Acinetobacter baumannii contains 16S rRNA with a base of sequence number 1. A standard strain composition for evaluating antibiotics contains Acinetobacter baumannii. A method for screening antibiotics comprises: a step of treating test compounds to Acinetobacter baumannii; and a step of confirming the suppression of film formation.
The session training will be divided into a warm-up, main exercise period, and cool-down, with a total duration of 60 minutes (guided by a PT). The training will be performed on a cycle ergometer, three times per week for 12 weeks. The duration of the main AE will be between 30-45 minutes and the intensity will be based on the maximal heart rate (HRmax), heart rate reserve (HRR), and the Borg Rating of Perceived Exertion Scale (Borg Scale), which will be monitored. The intensity of the AE program will be progressively increased according to each patient's response and tolerance but will be standardized as much as possible: 1) first two weeks, low to moderate intensity (60% HRmax or 9-11 on the Borg scale); 2) 2-6 weeks, moderate-intensity (55-70% HRmax or 12-14 on the Borg scale), and 3) last 6 weeks, high intensity interval training (HIT) (75-90% HRmax or 15-17 on the Borg scale; 4 min\*4 times HIT followed by 3 min of 70%HRmax in between) will be targeted per literature endorsements.
An abdominal elastic binder (girdles, trusses, abdominal belts, longuette, etc.) is a wide belt that surrounds the abdomen and supports the incision . Abdominal binder is routinely used after open surgery and Cesarean section, because it has been reported, according to a recent systematic review, to facilitate enhanced recovery after surgery (ERAS) such as pain relief, reduced risk of seroma formation, improved respiratory function, and assisted physical function using additional support to the lower abdominal musculature.

However, the routine use of abdominal binder after laparoscopy has been challenged due to a potential risk of postoperative pulmonary complications and deep venous thrombosis due to increased intra-abdominal pressure. Also, abdominal binders after laparoscopy have been criticized for being uncomfortable and hot to wear and for impinging the breast line in females. Therefore, some laparoscopists prefer the use of abdominal binder in patients undergoing laparoscopy, while other laparoscopists did not. However, there have been no studies exploring the efficacy of incision support using an elastic abdominal binder after laparoscopy to date. The investigators performed therefore a randomized controlled trial to determine the effect of post-laparoscopic abdominal binder use on ERAS in patients with gynecologic disease.
In controlled clinical trials performed in the United States, overdosage with FOSCAVIR was reported in 10 out of 189 patients. All 10 patients experienced adverse events and all except one made a complete recovery. One patient died after receiving a total daily dose of 12.5 g for three days instead of the intended 10.9 g. The patient suffered a grand mal seizure and became comatose. Three days later the patient expired with the cause of death listed as respiratory/cardiac arrest. The other nine patients received doses ranging from 1.14 times to 8 times their recommended doses with an average of 4 times their recommended doses. Overall, three patients had seizures, three patients had renal function impairment, four patients had paresthesias either in limbs or periorally, and five patients had documented electrolyte disturbances primarily involving calcium and phosphate. 

Overdose (up to 20 times the recommended dose) has been reported in post-marketing use of FOSCAVIR. Some of these post-marketing reports were relative overdoses in that the dose of FOSCAVIR had not been adjusted in patients with a reduced renal function. The pattern of adverse events associated with a FOSCAVIR overdose is consistent with the known adverse event profile of the drug. 

There is no specific antidote for FOSCAVIR overdose. Hemodialysis and hydration may be of benefit in reducing drug plasma levels in patients who receive an overdosage of FOSCAVIR, but the effectiveness of these interventions has not been evaluated. The patient should be observed for signs and symptoms of renal impairment and electrolyte imbalance. Medical treatment should be instituted if clinically warranted.
Cardiomyopathies encompass a spectrum of heart disorders with diverse causes and presentations. Fibrosis stands out as a shared hallmark among various cardiomyopathies, reflecting a common thread in their pathogenesis. This prevalent fibrotic response is intricately linked to the consequences of dysregulated extracellular matrix (ECM) remodeling, emphasizing its significance in the development and progression the disease. This review explores the ECM involvement in various cardiomyopathies and its impact on myocardial stiffness and fibrosis. Additionally, we discuss the potential of ECM fragments as early diagnosis, prognosis, and risk stratification. Biomarkers deriving from turnover of collagens and other ECM proteins hold promise in clinical applications. We outline current clinical management, future directions, and the potential for personalized ECM-targeted therapies with specific focus on microRNAs. In summary, this review examines the role of the fibrosis in cardiomyopathies, highlighting the potential of ECM-derived biomarkers in improving disease management with implications for precision medicine.
The sham procedure is developed by the tDCS device manufacturer, which allows using the same tDCS device and the same procedure (i.e., 10 sessions delivered during five consecutive days) for both the active and sham procedures. In the sham condition, the electrodes will be placed in the same positions as in the active group; however, the stimulator will be only active for initial and final ramp up/ramp down periods, in order to mimic the sensation of active stimulation. In addition, brief pulses of 110 μA will be administered every 550 ms in order to control impedance and keep the manipulator blinded to the active or sham condition.
Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
FIELD: medicine. SUBSTANCE: desired product is prepared of 2-mercapto-4,5-di(p-chlorophenyl)imidazole and hydrobromide of 2-morpholine ethyl bromide. Reaction is carried out in aqueous ethanol in the presence of NaOH. Thus obtained green-yellow oil is crystallized during sustaining. Yield of the base is 82.9 %. Said base is converted into hydrochloride by treatment with HCl. Yield of desired product is 96 %, its melting point is 241 C, its toxicity is 627 mg per 1 kg of body weight. EFFECT: increases activity of desired product. 1 tbl
SUICIDALITY AND ANTIDEPRESSANT DRUGS   
CONTRAVE® is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].
BACKGROUND: Social jetlag is a chronic disruption of sleep timing that is characterized by different sleep timing during workdays and free days. Social jetlag has been associated with disturbed glucose metabolism, insulin resistance, and increased risk of metabolic syndrome and type 2 diabetes. In this study, we aim to investigate whether a combination of bright light therapy in the morning, bright light reduction in the evening and sleep advance instructions for 3 weeks reduces social jetlag and if this results in improvement of glycemic and metabolic control, sleep, mood and quality of life after 3 and 12 weeks in people with prediabetes and type 2 diabetes and to assess possible mediators, compared to regular sleep habits.
METHODS: In this randomized controlled trial, 60 people with prediabetes or type 2 diabetes with > 1 h social jetlag will be recruited. The intervention consists of bright light therapy (5000 lx) emitted by Vitamine-L (Lumie, UK) for 30 min each morning, combined with the advice to follow sleep advance instructions and to wear bright light-dimming goggles every evening for a period of 3 weeks. The control group adheres to their regular sleep habits and conditions. The primary outcome is glycated hemoglobin (HbA1c) after 12 weeks comparing the intervention and control in an intention-to-treat analysis. Secondary outcomes at 3 and 12 weeks are (1) social jetlag; (2) insulin sensitivity, fasting blood glucose, glucose-lowering medication use, and frequency of perceived hypoglycemia; (3) metabolic outcomes, including body mass index (BMI), waist circumference, body fat percentage, and blood pressure; (4) mood, including depression, fatigue and anxiety (measured with questionnaires); and (5) quality of life measured using EQ5D questionnaire. To assess other factors that might play a role as possible mediators, we will measure (para)sympathetic nervous system activity assessed with ECGs and electrochemical skin conductance tests, sleep quality and sleep phase distribution assessed with a sleep measuring headband (ZMax), the Dim Light Melatonin Onset in saliva samples (in a subgroup) at 3 and 12 weeks, the feeling of satiety and satiation with a 10-cm visual analog scale (VAS), diet using a food frequency questionnaire, and physical activity using an accelerometer (ActiGraph).
DISCUSSION: Social jetlag can contribute to poorer glycemic control and metabolic control in those with type 2 diabetes. With this intervention, we aim to reduce social jetlag and thereby improve glycemic and metabolic control. This could offer a way to improve overall population health and to reduce the disease burden of type 2 diabetes.
TRIAL REGISTRATION: ISRCTN registry ISRCTN11967109 . Registered on 9 May 2024.
The invention discloses a medicinal composition for treating gynecological inflammations. The medicinal composition is characterized in that the medicinal composition comprises the following components, by weight, 5 parts of a chitosan oligosaccharide, 1 part of a Salvia miltiorrhiza extract, 0.65 parts of a Chinese angelica extract paste, and 0.75 parts of a Radix Astragali extract liquid. The medicinal composition of the invention is applied to wound restoration experiments, and results show that wounds are basically healed and there are no obvious scars. Cell proliferation tests prove that the medicinal composition is good for cell propagation and regeneration. The medicinal composition is applied to in vitro bacteriostatic tests, and results show that the medicinal composition has a stronger bacteriostatic capability than Anfushu, Ruchuangning and wound restoration agents. Acute toxicity tests of the medicinal composition are carried out in the invention, and the test medicinal composition is regarded as a nontoxic medicine through determining according to acute toxicity grading standards. So the medicinal composition of the invention can be used for treating the gynecological inflammations, and has large clinical application values.
In the 1990s, the identification of a non-selective ion channel, especially responsive to capsaicin, revolutionized the studies of somatosensation and pain that were to follow. The TRPV1 channel is expressed mainly in neuronal cells, more specifically, in sensory neurons responsible for the perception of noxious stimuli. However, its presence has also been detected in other non-neuronal cells, such as immune cells, β- pancreatic cells, muscle cells and adipocytes. Activation of the channel occurs in response to a wide range of stimuli, such as noxious heat, low pH, gasses, toxins, endocannabinoids, lipid-derived endovanilloid, and chemical agents, such as capsaicin and resiniferatoxin. This activation results in an influx of cations through the channel pore, especially calcium. Intracellular calcium triggers different responses in sensory neurons. Dephosphorylation of the TRPV1 channel leads to its desensitization, which disrupts its function, while its phosphorylation increases the channel's sensitization and contributes to the channel's rehabilitation after desensitization. Kinases, phosphoinositides, and calmodulin are the main signaling pathways responsible for the channel's regulation. Thus, in this review we provide an overview of TRPV1 discovery, its tissue expression as well as on the mechanisms by which TRPV1 activation (directly or indirectly) induces pain in different disease models.
Participants will receive 6 therapy sessions starting with 3 sessions of mindful emotion awareness followed by 3 sessions of cognitive flexibility. Each session will have a duration of approximately 1 hour. Treatment will follow the UP manual by Barlow et al. (2018).
Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.